Preparing for phase II/III HIV vaccine trials in Africa.
Before performing phase II/III clinical trials in Africa, preliminary studies, including assessment and building up of clinical and laboratory infrastructures, estimates of human immunodeficiency virus incidence, investigation of the background immune response, and evaluation of the cross-clade immune response, need to be done. Plans and ongoing work in the context of the AIDS Vaccine Integrated Project and some preliminary data are presented.
Vardas
Eftyhia
E
Perinatal HIV Research Unit, University of the Witwatersrand, PO Box 114, Diepkloof 1864, Johannesburg, South Africa. vardase@mweb.co.za
Buttò
Stefano
S
Glashoff
Richard
R
Malnati
Mauro S
MS
Poli
Guido
G
Clerici
Mario
M
D016915:AIDS Vaccines / Q000276:immunology; D000349:Africa / Q000453:epidemiology; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006678:HIV / Q000276:immunology; D015658:HIV Infections / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy*; D006801:Humans; D007753:Laboratories / Q000706:statistics & numerical data
D016915:AIDS Vaccines